Co-development of tumor microenvironment panel with ACT Genomics to assist in predicting immunotherapy response in cancer patients
Immunotherapy has welcomed a new era of cancer treatment. By utilizing the patient's own body's natural defenses to fight cancer, the patients that respond to immunotherapy have great prognoses. However, not every cancer patient responds well to immunotherapy. There are three indications that are currently believed to indicate immunotherapy response:
